Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin
The soon-to-issue patent, titled, “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.
- The soon-to-issue patent, titled, “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.
- The USPTO issues an NoA after making the determination that a patent should be granted from an application.
- To date, the USPTO has issued seven NoAs for patent applications claiming compounds in the EVM201 and EVM301 Series.
- Two applications are now granted patents that specifically protect EB-373; and one application is now a granted patent covering certain EVM301 compounds.